NCT06839339View on ClinicalTrials.gov

Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

January 30, 2027

Conditions
Wet Age-related Macular Degeneration (wAMD)
Interventions
DRUG

AL-001

Administered via suprachoroidal space injection.

DRUG

Aflibercept

Intravitreal injection

Trial Locations (1)

Unknown

Chinese Academy of Medical Sciences & Peking Union Hospital, Beijing

All Listed Sponsors
lead

Beijing Anlong Biopharmaceutical Co., Ltd.

INDUSTRY